Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-8186

6 FDA label images from Preferred Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-8186). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical Structure (Spl Image1 Structure1)
Chemical structure of Losartan Potassium, showing the arrangement of atoms including chlorine, hydroxyl, and potassium ion groups in the molecule.*
FDA Label Image

Figure 1 (Spl Image2 Figure1)

Figure 1 (Spl Image2 Figure1)
A line graph comparing the percentage of patients with a primary endpoint over 66 study months between Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months and the y-axis shows the percentage of patients with the primary endpoint. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium versus Atenolol.*
FDA Label Image

Figure 2 (Spl Image3 Figure2)

Figure 2 (Spl Image3 Figure2)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months between two treatments: Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows a lower stroke incidence in patients treated with Losartan Potassium, with an adjusted risk reduction of 25% (p=0.001). The x-axis represents study months and the y-axis the percentage of affected patients.*
FDA Label Image

Figure 3 (Spl Image4 Figure3)

Figure 3 (Spl Image4 Figure3)
A forest plot chart comparing primary endpoint events and stroke rates between Losartan Potassium and Atenolol within demographic subgroups. The chart shows hazard ratios and 95% confidence intervals across categories including age, gender, race, ISH, diabetes, and history of cardiovascular disease. Symbols denote event rates and sample sizes for each subgroup.*
FDA Label Image

Figure 4 (Spl Image5 Figure4)

Figure 4 (Spl Image5 Figure4)
A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo. The x-axis represents time in months (0 to 48), and the y-axis represents the percentage of patients with an event (0% to 60%). The graph shows two curves: a solid line for Losartan Potassium and a dotted line for placebo, with a noted risk reduction of 16.1% and a p-value of 0.022.*
FDA Label Image

Losartan Potassium Tab Usp 100mg (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)

Losartan Potassium Tab Usp 100mg (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)
Label for Losartan Potassium USP 100 mg film-coated tablets, generic for Cozaar, by Preferred Pharmaceuticals Inc. The label includes dosage instructions in English and Spanish, storage warnings, and manufacturer details—Solco Healthcare U.S., LLC, Cranbury, NJ. It features barcode and QR code areas, and space for batch, expiration date, and product number information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.